539 related articles for article (PubMed ID: 28461650)
1. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
[TBL] [Abstract][Full Text] [Related]
2. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F
Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.
Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R
ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
[TBL] [Abstract][Full Text] [Related]
7. Association between anti-PL7 antibodies and increased fibrotic component in patients with antisynthetase syndrome and interstitial lung disease: a cross-sectional study.
Rivero-Gallegos D; Mejía M; Rocha-González HI; Huerta-Cruz JC; Falfán-Valencia R; Ramos-Martínez E; Mateos-Toledo HN; Castillo-López MF; Rodríguez-Torres YK; Lira-Boussart V; Rojas-Serrano J
Clin Rheumatol; 2024 Jun; 43(6):1971-1978. PubMed ID: 38642252
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.
Marie I; Josse S; Decaux O; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Hachulla E; Vittecoq O; Menard JF; Jouen F; Dominique S
Eur J Intern Med; 2013 Jul; 24(5):474-9. PubMed ID: 23375620
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome.
Zhang Y; Ge Y; Yang H; Chen H; Tian X; Huang Z; Liu S; Lu X; Wang G
Clin Rheumatol; 2020 Aug; 39(8):2417-2424. PubMed ID: 32144624
[TBL] [Abstract][Full Text] [Related]
10. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
Hervier B; Devilliers H; Stanciu R; Meyer A; Uzunhan Y; Masseau A; Dubucquoi S; Hatron PY; Musset L; Wallaert B; Nunes H; Maisonobe T; Olsson NO; Adoue D; Arlet P; Sibilia J; Guiguet M; Lauque D; Amoura Z; Hachulla E; Hamidou M; Benveniste O
Autoimmun Rev; 2012 Dec; 12(2):210-7. PubMed ID: 22771754
[TBL] [Abstract][Full Text] [Related]
11. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use.
Stanciu R; Guiguet M; Musset L; Touitou D; Beigelman C; Rigolet A; Costedoat-Chalumeau N; Allenbach Y; Hervier B; Dubourg O; Maisonobe T; Charuel JL; Behin A; Herson S; Amoura Z; Grenier P; Benveniste O
J Rheumatol; 2012 Sep; 39(9):1835-9. PubMed ID: 22859355
[TBL] [Abstract][Full Text] [Related]
12. Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification.
Wu S; Xiao X; Zhang Y; Zhang X; Wang G; Peng Q
Ann Rheum Dis; 2024 May; 83(6):775-786. PubMed ID: 38395605
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF).
Mejía M; Herrera-Bringas D; Pérez-Román DI; Rivero H; Mateos-Toledo H; Castorena-García P; Figueroa JE; Rojas-Serrano J
Respir Med; 2017 Feb; 123():79-86. PubMed ID: 28137500
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti-aminoacyl-tRNA synthetase antibodies: A single center experience.
Zhang D; Wang H; Zhou X; Yang J; Liu Y; Wang W; Jiang P; Fan B
Immun Inflamm Dis; 2023 Nov; 11(11):e1085. PubMed ID: 38018600
[TBL] [Abstract][Full Text] [Related]
16. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
Srivastava P; Dwivedi S; Misra R
Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).
Rojas-Serrano J; Herrera-Bringas D; Mejía M; Rivero H; Mateos-Toledo H; Figueroa JE
Clin Rheumatol; 2015 Sep; 34(9):1563-9. PubMed ID: 26219488
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.
Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W
Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
Pinal-Fernandez I; Casal-Dominguez M; Huapaya JA; Albayda J; Paik JJ; Johnson C; Silhan L; Christopher-Stine L; Mammen AL; Danoff SK
Rheumatology (Oxford); 2017 Jun; 56(6):999-1007. PubMed ID: 28339994
[TBL] [Abstract][Full Text] [Related]
20. Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease.
Zhao N; Jiang W; Wu H; Wang P; Wang X; Bai Y; Li Y; Tang Y; Liu Y
Front Immunol; 2022; 13():872615. PubMed ID: 36032132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
